Tags

Type your tag names separated by a space and hit enter

Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
Acta Haematol. 2020; 143(5):417-424.AH

Abstract

Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease.

Authors+Show Affiliations

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel, Shir_hazan@yahoo.com. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Shir_hazan@yahoo.com.Hematology Department, Rabin Medical Center, Petah Tikva, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.Cardiology Department, Rabin Medical Center, Petah Tikva, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.Cardiology Department, Rabin Medical Center, Petah Tikva, Israel. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32396903

Citation

Tal, Shir, et al. "Venous Thromboembolism Complicated With COVID-19: what Do We Know so Far?" Acta Haematologica, vol. 143, no. 5, 2020, pp. 417-424.
Tal S, Spectre G, Kornowski R, et al. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol. 2020;143(5):417-424.
Tal, S., Spectre, G., Kornowski, R., & Perl, L. (2020). Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematologica, 143(5), 417-424. https://doi.org/10.1159/000508233
Tal S, et al. Venous Thromboembolism Complicated With COVID-19: what Do We Know so Far. Acta Haematol. 2020;143(5):417-424. PubMed PMID: 32396903.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? AU - Tal,Shir, AU - Spectre,Galia, AU - Kornowski,Ran, AU - Perl,Leor, Y1 - 2020/05/12/ PY - 2020/04/20/received PY - 2020/04/27/accepted PY - 2020/5/13/pubmed PY - 2020/10/21/medline PY - 2020/5/13/entrez KW - COVID-19 KW - Deep vein thrombosis KW - Pulmonary emboli KW - Venous thromboembolism SP - 417 EP - 424 JF - Acta haematologica JO - Acta Haematol VL - 143 IS - 5 N2 - Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease. SN - 1421-9662 UR - https://www.unboundmedicine.com/medline/citation/32396903/Venous_Thromboembolism_Complicated_with_COVID_19:_What_Do_We_Know_So_Far L2 - https://www.karger.com?DOI=10.1159/000508233 DB - PRIME DP - Unbound Medicine ER -